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Purpose: To compare the effects on tolerability, tear osmolarity, and intraocular pressure 
(IOP)-lowering effect of switching from benzalkonium chloride (BAK) containing prostaglandin 
analog (PGA) latanoprost to preservative-free tafluprost.
Patients and methods: Thirty patients with open-angle glaucoma (N = 60 eyes), 26 women 
(87%) and four men (13%) aged 64.1 (SD 14.1) years, showing abnormal values of tear osmo-
larity, corneal fluorescein staining, tear film break-up time (TBUT), or subjective discomfort 
with current latanoprost treatment were included. After tear osmolarity (TearLab™ Osmolarity 
System), TBUT, corneal fluorescein staining, and baseline IOP (Goldmann tonometer) measure-
ments and the completion of Ocular Surface Disease Index and Ocular Surface Symptoms in 
Glaucoma Scale questionnaires, patients were assigned to preservative-free tafluprost treatment. 
Measurements were repeated 2, 6 and 12 weeks after change of medication.
Results: No statistically significant differences in IOP were observed 2, 6, and 12 weeks after 
switching to preservative-free tafluprost. Mean IOP at baseline was 16.4 mmHg (SD 2.9), after 
2 weeks 16.2 mmHg (2.8), after 6 weeks 16.2 (2.6), and after 12 weeks 16.3 mmHg (2.3). 
Mean tear osmolarity decreased significantly from 315.7 mOsm/L (SD 15.1) at baseline to 
308.0 ± 14.4 mOsm/L (P = 0.002), 301.7 ± 14.5 mOsm/L (P , 0.001), and 302.0 ± 9.9 mOsm/L 
(P , 0.001) 2, 6, and 12 weeks after changing medication to preservative-free tafluprost, 
  respectively. Tear osmolarity was lower in 37 eyes (61.7%) after 2 weeks, in 46 eyes (76.7%) 
after 6 weeks, and in 49 eyes (81.7%) after 12 weeks (P , 0.005; t-test). At baseline corneal 
fluorescein staining was observed in 43 eyes (71.7%), after 2 weeks in 34 eyes (56.7%), after 
6 weeks in 12 eyes (20.0%), and after 12 weeks in 7 eyes (11.7%) (P , 0.005; McNemar test). 
Mean TBUT increased from 3.7 seconds (SD 1.1) at baseline to 4.1 seconds (SD 1.0) at week 2, 
5.2 seconds (SD 1.5) at week 6, and 6.5 seconds (SD 1.5) at week 12 (P , 0.001; t-test). The 
number of patients expressing discomfort with latanoprost diminished from 30 (100%) at baseline, 
to 19 (63.3%) after week 2, and to 11 (36.6%) (P , 0.05; McNemar test) after 12 weeks.
Conclusion: Preservative-free tafluprost is better tolerated than BAK-containing latanoprost, 
showing lower tear osmolarity levels while maintaining effective IOP control.
Keywords: glaucoma, preservatives, tafluprost, osmolarity, intraocular pressure, prostaglandin   
analogs, BAK, tolerability
Introduction
Glaucoma is a chronic, potentially blinding condition and one of the leading causes of 
blindness in the world. Medical therapy is the initial option in the treatment of glaucoma.1 
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However, adverse effects associated with topical medication 
may have a negative effect on patient adherence to medical 
treatment, doctor–patient relationship, and patient quality 
of life.2 Currently available topical glaucoma medication in 
multidose bottles typically contain preservatives in addition 
to the active component. After instillation, eye drops interact 
with ocular surface tissues.3 This interaction can involve both 
the active agent and the preservatives. Preservatives in eye-
drops are used to inhibit microbial growth in the bottle, which 
allows safe use of the multidose containers.   Preservatives 
also prevent biodegradation and support the maintenance 
of drug potency.4 Benzalkonium chloride (BAK), the most 
widely used preservative in topical glaucoma medications, 
is a cationic surfactant that adheres to microorganism cell 
membranes, increases membrane permeability, and leads 
to cell lysis.5 It has been demonstrated in various studies 
that BAK has also a toxic effect on the ocular surface. This 
preservative decreases tear film stability and turnover, causes 
inflammatory cell infiltration, and induces conjunctival 
and corneal epithelial cell abnormalities.6 The tear film is a 
dynamic structure comprising of lipid, aqueous, and mucin 
layers. Its production and turnover is essential for maintaining 
the health of the ocular surface. The formation and stability 
of the tear film in both health and disease are dependent upon 
the physical properties of the tear fluid. The tear film plays 
an important role in nourishing, lubricating, and protecting 
the ocular surface. A dysfunction of any of the layers of the 
tear film may result in dry eye disease.7 Disruption of the 
homeostasis of the tear film results in ocular surface inflam-
mation, which may lead to cell damage. Abnormalities of 
any tear component can result in tear film instability and 
hyperosmolarity.8 Osmolarity is the measure of solute concen-
tration, defined as the number of osmoles of solute per liter 
of solution (Osm/L).9,10 As a measure of tear film chemistry, 
osmolarity can be useful for evaluating the quality of patients’ 
tears. Tear film osmolarity in normal   volunteers seems to be 
in the range of 290–300 mOsm/L. Studies reveal an average 
osmolarity of around 302 mOsm/L.11–14   Considering that tears 
are physiologically derived from blood, normal tear osmolar-
ity should be observed around 290 mOsm/L. Osmolarity of 
tears specifically refers to the concentration of small proteins 
and electrolytes, including sodium, potassium, and chloride. 
Although measuring osmolarity does not reveal the exact 
chemical composition of tears, it quantifies the concentra-
tion of the different components. Research has shown that 
knowledge of tear film osmolarity can be clinically valuable 
for assessing dry eye disease. Human tears are isotonic with 
a 0.9% sodium   chloride solution15,16 and the recommendation 
for adjusting the osmotic concentration of eye drops to this 
presumed tonicity has found general acceptance.10 Tear hyper-
osmolarity is regarded as a central mechanism causing dry 
eye symptoms and ocular surface inflammation by activating 
a cascade of inflammatory events and the release of inflam-
matory mediators into the tears. Epithelial damage involves 
cell death by apoptosis, a loss of goblet cells, and a reduc-
tion in mucus secretion that leads to tear film instability.17,18 
This instability exacerbates ocular surface hyperosmolarity, 
thereby creating a vicious circle.19 Recently, Lemp reported 
that osmolarity is the best single metric both to diagnose and 
classify dry eye disease.19 Tafluprost is a novel prostaglandin 
analog (PGA) that has been approved for ophthalmic use in a 
number of markets worldwide. The drug is currently marketed 
under the brand names Taflotan and Taflotan sine (Santen Oy, 
Tampere, Finland), Tapros (Santen   Pharmaceutical Co Ltd, 
Osaka, Japan), and Saflutan (Merck Sharp and Dohme, 
Whitehouse Station, NJ). Among all widely used PGA’s, 
tafluprost is the first and only preparation available in a 
preservative-free formulation. The aim of the current study 
was to compare the effects on tolerability, tear osmolarity, and 
intraocular pressure (IOP) lowering after switching from BAK-
preserved latanoprost to preservative-free PGA tafluprost.
Material and methods
Study design
This was a prospective, observer-masked study over a period 
of 12 weeks. The study was conducted in accordance with 
the Declaration of Helsinki. All subjects read and signed an 
informed consent, and the study was approved by the Kaunas 
University of Medicine Institutional Review Board.
Patients
Thirty patients with open-angle glaucoma (N = 60 eyes) were 
included in the study. Patients were aged at least 18 years 
and willing to sign the informed consent prior to initiation of 
study. Inclusion criteria were: clinical diagnosis of open-  angle 
glaucoma (with or without pseudoexfoliation or pigment dis-
persion component) in at least one eye with best-corrected 
visual acuity 20/40 (or equivalent) or better, at least mild dry 
eye according to Ocular Surface Disease Index (OSDI) score 
(while score 0 corresponds to never had any ocular surface 
disease symptoms) and/or corneal fluorescein staining in 
at least one eye (mild staining, less than 10% coverage of 
corneal surface; moderate, 10%–50% of corneal surface; 
severe, more than 50% of corneal surface), IOP controlled 
with monotherapy using latanoprost 50 µg/mL for not less 
than 1 continuous month immediately prior to the study visit. 
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Patients with any abnormality preventing reliable applanation 
tonometry in the study eye(s), having dry eye treated with 
the use of punctual plugs, punctual cautery, cyclosporine, 
topical ocular corticosteroids, using artificial tears not dis-
continued prior to first study visit, having keratorefractive 
ocular laser procedures, corneal surgery or surgery to the 
corneal surface within one year prior to first visit, patients 
who have undergone intraocular or extraocular surgery 
ocular laser surgery in either eye within 6 months, patients 
with progressive retinal or optic nerve disease, patients with 
severe central visual field loss, patients with any history of 
infectious or inflammatory ocular conditions, patients having 
ocular trauma within 6 months, any systemic medications on 
a chronic basis that have not been on a stable dosing regimen 
for 1 month prior to the study, and history of intolerance or 
hypersensitivity to any component of the test articles were 
excluded from the study.
Measurements and statistical analysis
After baseline IOP (Goldmann applanation tonometry) and 
tear osmolarity (TearLab™ Osmolarity System; TearLab, 
San Diego, CA) measurements, answering two question-
naires, OSDI and Ocular Surface Symptoms in Glaucoma 
Scale (OSSG), patients were switched to preservative-free 
tafluprost for 12 weeks. IOP and tear osmolarity were mea-
sured and corneal staining evaluated at 2, 6, and 12 weeks. 
All measurements were done at the same time of day (3 pm). 
At the final study visit (week 12) patients filled OSSG and 
OSDI questionnaires again.
Several hypotheses were tested: primary, tear osmolarity 
level is restored after switching to preservative-free glaucoma 
medication; secondary, patients prefer preservative-free 
medication; tertiary, no statistically significant difference in 
IOP level between BAK-containing and preservative-free 
prostaglandin analogs. The primary efficacy variable was 
tear film osmolarity level as measured by TearLab [Osm/L]. 
Secondary efficacy variables were the IOP-lowering effect, 
tear film break-up time (TBUT), OSSG, and OSDI.
Descriptive statistics were obtained for the resulting 
measurements. In the event that significance was achieved 
by repeated analysis of variance (ANOVA) measurements, 
the Fisher’s and Bonferroni models were applied. Changes 
in individual parameters were examined by paired   Student’s 
t-test, considering values of P , 0.05 as statistically 
  significant. To test the hypothesis that the mean difference 
between two measurements is zero, Wilcoxon signed-rank 
test was used. Changes in various parameters were analyzed 
by Pearson’s correlation analysis.
Results
Patient demographics and diagnoses
Thirty patients with open-angle glaucoma (60 eyes), 
26 women (86.7%), four men (13.3%), aged 64.2 years (SD 
13.9 years) (range, 35–79 years) were recruited (Table 1). 
After baseline measurements, patients were assigned to 
preservative-free tafluprost treatment and measurements were 
repeated 2, 6, and 12 weeks after switching to preservative-
free tafluprost. At baseline all patients reported subjective 
discomfort with their current latanoprost treatment.
Osmolarity
Mean tear osmolarity level at baseline (BAK-preserved latano-
prost) was 315.7 mOsm/L (SD: 15.1) (Figure 1). At baseline, 
osmolarity was not statistically significant between the right 
and left eyes of patients. Compared to baseline, tear osmolar-
ity decreased in 37 eyes (61.7%) after 2 weeks, in 46 eyes 
(76.7%) after 6 weeks, and in 49 eyes (81.7%) after 12 weeks 
(P , 0.005; t-test for paired samples) (Figure 1). Mean 
osmolarity decreased significantly 2, 6, and 12 weeks after 
changing medication to 308.0 ± 14.4 mOsm/L (P = 0.002 vs 
baseline), 301.7 ± 14.5 mOsm/L (P , 0.001 vs baseline), and 
302.0 ± 9.9 mOsm/L (P , 0.001), respectively (Figure 2).
TBUT and fluorescein staining
Mean TBUT (±SD) increased significantly from 3.7 ± 1.1 
seconds at baseline to 4.1 ± 1.0 seconds after 2 weeks, 
5.2 ± 1.5 seconds after 6 weeks, and 6.5 ± 1.5 seconds after 
12 weeks. Forty-five eyes (75.0%) showed abnormal fluores-
cein staining of the cornea at baseline. The number of eyes 
with abnormal values decreased during the course of the 
study to 35 (58.3%), 21 (35.0%), and seven eyes (11.7%) at 
weeks 2, 6, and 12, respectively (Table 2).
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Figure 1 Distribution of osmolarities at latanoprost baseline and 2, 6, and 12 weeks 
after changing medication to preservative-free tafluprost.
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Effect on iOP
Mean IOP (±SD) was 16.4 ± 3.0 mmHg at treated   baseline. 
At baseline, difference in IOP values between right and 
left eyes was not statically significant. IOP remained 
unchanged at 2 weeks (16.3 ± 2.9 mmHg; P = 0.651), 
6 weeks (16.2 ± 2.7 mmHg; P = 0.673), and 12 weeks 
(16.3 ± 2.3 mmHg; P = 0.820) after changing medication 
from preserved latanoprost to preservative-free tafluprost 
(Figure 3).
Subjective complaints
Subjective complaints decreased with every follow-up visit of 
tafluprost treatment. At the final visit 12 weeks after changing 
medication to preservative-free tafluprost, only 11 (36.7%) 
out of 30 patients at baseline were still expressing subjective 
complaints (Table 2).
OSDi and OSSG questionnaires
The OSDI questionnaire showed that during latanoprost 
baseline, 16 patients (53.3%) had mild dry eye complaints, 
while after 12 weeks the number of patients with these symp-
toms was reduced to eight (26.7%) (Figure 4). The OSSG 
questionnaire revealed that 40.0% of patients felt dry eye 
symptoms some of the time at baseline. Twelve weeks after 
changing medication to preservative-free tafluprost, these 
symptoms remained in only 26.7% of patients (  Figure 5). 
Using the OSDI questionnaire, our study revealed that 
16 patients (53.3%) had mild complaints typical to dry eye 
syndrome, while 12 patients (40.0%) had no complaints at 
all. Twelve weeks after changing medication to preservative-
free tafluprost, the number of patients with mild complaints 
was reduced to eight (26.6%). Nineteen patients (63.3%) 
reported no complaints at all. The OSSG questionnaire 
showed that 12 patients (40%) had dry eye symptoms some 
of the time and four (13.3%) most of the time, while 40% 
had no complaints. After 12 weeks of tafluprost treatment, 
dry eye symptoms present “only some of the time” were 
noticed by eight patients (26.7%), while the number of 
patients reporting dry eye symptoms present “most of the 
time” decreased to three (10.0%). Consequently the num-
ber of patients reporting “no complaints” increased to 17 
(56.7%).
Discussion
Currently, the only proven and accepted method of preserv-
ing visual function in patients with glaucoma is to lower IOP. 
Although a variety of glaucoma genotypes and phenotypes 
exist, reduction of IOP remains the only modifiable risk factor 
delaying or preventing visual loss.1,20–22
Chronic use of most IOP-lowering medications is associ-
ated with various adverse reactions: allergies,   conjunctivitis, 
contact dermatitis, punctate keratitis, or even failure of 
  filtration surgery.23–25 This toxicity seems rather to be 
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Figure  2  Mean  osmolarity  and  95%  confidential  intervals  (CI)  at  baseline 
(latanoprost) and 2, 6, and 12 weeks after changing medication to preservative-free 
tafluprost.
Table 1 Patient demographics (n = 30)
Mean age (years) 64.2
  Range (years) 35–79
  SD 13.9
Sex
  Male 26
  Female 4
Glaucoma since years (mean) 3.6
Range (years) 0.5–15
Abbreviation: SD, standard deviation.
Table 2 Changes of patient complaints, mean tear film break-up time (±SD) and abnormal corneal fluorescein staining at baseline 
(latanoprost), 2, 6, and 12 weeks after changing medication to preservative-free tafluprost
Baseline Week 2 Week 6 Week 12 P-value (12 weeks vs  
baseline)
Dry eye complaints n = 30 (patients) 30 (100%) 19 (63.3%) 11 (36.7%) 11 (36.7%) ,0.05 (McNemar)
Tear film break-up time (seconds) n = 60 (eyes) 3.7 ± 1.1 4.1 ± 1.0 5.2 ± 1.5 6.5 ± 1.5 ,0.001 (paired t-test)
Abnormal fluorescein staining of the cornea  
n = 60 (eyes)
45 (75.0%) 35 (58.3%) 21 (35%) 7 (12%) ,0.005 (McNemar)
Abbreviation: SD, standard deviation.
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associated with the preservative BAK than with the active 
component of the medication.26 From this point of view, 
preservative-free preparations in unit-dose presentation, are 
a viable alternative to traditional multidose bottles.
Our study found no statistically significant difference in 
the IOP levels of patients treated with the preservative-free 
prostaglandin analog tafluprost and the BAK-preserved for-
mulation of the prostaglandin analog latanoprost. The average 
latanoprost baseline IOP (16.4 ± 2.9 mmHg) was similar to 
the average IOP after 3 months of preservative-free tafluprost 
therapy (16.3 ± 2.3 mmHg). Our results confirm the findings 
of Uusitalo and colleagues who found that IOP remained 
unchanged 12 weeks after changing medication from BAK-
preserved latanoprost to preservative-free tafluprost.27 
Miyashiro and colleagues found that changing medication 
from BAK-preserved latanoprost 0.005%   monotherapy to a 
sofZia™-(Alcon Inc, Fort Worth, TX) preserved formulation 
of   travoprost 0.004% resulted in a similar IOP control.28 The 
findings from these studies show that IOP is not changed 
significantly after changing medication from BAK-containing 
to preservative-free or sofZia™-preserved prostaglandin 
analog formulations. Therefore BAK might not be necessary 
for these prostaglandin analogs to enhance their corneal pen-
etration and to achieve better IOP control.29 This may be due 
to the lipophilic nature of prostaglandin analogs. Hamacher 
and colleagues demonstrated in a randomized investigator 
masked cross-over study that BAK as a preservative has no 
influence on the effectiveness of tafluprost. IOP was measured 
four times per day at 1 and 4 weeks of treatment. There was 
no statistically significant difference between BAK-preserved 
tafluprost and preservative-free tafluprost (P = 0.957).30
Several studies have revealed discrepancies between dry 
eye symptoms and clinical signs. Signs specific for a single 
subtype of dry eye demonstrated poor correlation to disease 
severity in milder patients. Tear film osmolarity was found to 
be the single best marker of disease severity across normal, 
mild or moderate, and severe dry eye disease categories.12 Our 
study aimed to investigate osmolarity levels after switching 
from a BAK-containing PGA formulation to preservative-free 
tafluprost. Mean tear osmolarity level with BAK-preserved 
latanoprost was 315 mOsm/L. Two weeks after switching to 
preservative-free tafluprost, mean osmolarity decreased sta-
tistically significantly to 308 mOsm/L, and to 302 mOsm/L 
after 12 weeks (P , 0.001; t-test). According to Lemp and 
colleagues, the most sensitive threshold between normal and 
mild or moderate subjects was found to be 308 mOsm/L. At 
a cut-off of 312 mOsm/L, tear hyperosmolarity exhibited 
73% sensitivity and 92% specificity. By contrast, the other 
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Figure 3 Mean intraocular pressure (IOP) and 95% confidential intervals (CI) at 
baseline (preserved latanoprost) and 2, 6, and 12 weeks after changing medication 
to preservative-free tafluprost.
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Figure  4  Severity  of  ocular  symptoms  at  baseline  (preserved  latanoprost)  and   
12 weeks after changing medication to preservative-free tafluprost evaluated by 
using the OSDi questionnaire.
Abbreviation: OSDi, Ocular Surface Disease index.
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Figure 5 Frequency of ocular symptoms at baseline (preserved latanoprost) and 
12 weeks after changing medication to preservative-free tafluprost evaluated by 
using the OSSG questionnaire.
Abbreviation: OSSG, Ocular Surface Symptoms in Glaucoma Scale.
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common tests exhibited either poor sensitivity (corneal 
staining, 54%; conjunctival staining, 60%; meibomian gland 
grading, 61%) or poor specificity (TBUT, 45%; Schirmer 
test, 51%). Differences in osmolarity were found to correlate 
with increasing disease severity (r2 = 0.32).31 Another study 
by Luo and colleagues proved that hyperosmolarity induces 
apoptosis of human corneal epithelial cells.32
Evaluating other common signs for ocular surface 
disease such as a decrease in TBUT, we found that TBUT 
increased statistically significantly from 3.7 ± 1.1 seconds 
at latanoprost baseline to 6.5 ± 1.5 seconds 12 weeks 
after changing medication to preservative-free tafluprost 
(P , 0.001). Abnormal corneal fluorescein staining was 
observed in 45 (75.0%) eyes at baseline. Twelve weeks after 
the change of medication only seven (11.7%) eyes showed 
abnormal values (P , 0.005). This improvement of signs 
of the ocular surface after changing medication from a 
BAK-preserved to a preservative-free prostaglandin analog 
medication confirm the findings of Uusitalo and colleagues. 
They showed that abnormal corneal fluorescein staining 
reduced statistically significantly from 81.6% of cases to 
40.6%. TBUT improved statistically significantly from 
4.5 ± 2.5 seconds to 7.8 ± 4.9 seconds.27
Leung and colleagues showed that 59% of patients with 
glaucoma or ocular hypertension have symptoms of ocular 
surface disease, with 27% being severe.33 The overall OSDI 
score is defined as normal (0–12 points), mild (13–22 points), 
moderate (23–32 points), or severe (33–100 points) ocular 
surface disease.34 Severity of patient complaints with their 
medication decreased during the course of our study. Using 
the OSDI questionnaire the study revealed that 53.3% of 
patients had mild complaints typical for dry eye syndrome, 
while 40.0% had no complaints at all. Twelve weeks after 
changing the medication to preservative-free tafluprost, the 
number of patients with mild complaints was reduced from 
53.3% at baseline to 26.6%. Furthermore, 63.3% of patients 
reported no complaints at all. The OSSG questionnaire 
showed great improvement with respect to the frequency 
of ocular symptoms: 12 weeks after change of medication 
to preservative-free tafluprost, dry eye symptoms improved 
significantly (P . 0.005). Data from Uusitalo and col-
leagues revealed that during treatment with preservative-free 
tafluprost the number of patients having dry eye sensation 
decreased from 64.6% to 39.4%.27 According to Schiffman 
and colleagues, the OSDI is a valid and reliable instrument 
for measuring the severity of dry eye disease, and it possesses 
psychometric properties that are needed as an end point 
in clinical trials.35 Fechtner and colleagues found a good 
correlation between OSDI symptoms and the number and 
duration of glaucoma treatments used.36 Other clinical   studies 
have demonstrated that the withdrawal of preservatives 
may reduce adverse effects associated with eye drops while 
preservative-free glaucoma treatments may have clinically 
relevant benefits for patients.37,38 The findings of the present 
study confirm the results from these prior studies.
Conclusion
Our results suggest that a change of medication from BAK-
preserved latanoprost to preservative-free tafluprost is able to 
normalize tear osmolarity, to improve subjective symptoms, 
reduce corneal fluorescein staining, and improve TBUT while 
maintaining effective IOP control. These findings may be of 
specific importance for all glaucoma patients with sensitive 
and dry eyes.
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